The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV
Jordan E. Lake, Douglas Kitch, Amy Kantor, Raja Muthupillai, Karin L. Klingman, Christina Vernon, Pablo F. Belaunzarán-Zamudio, Carl J. Fichtenbaum, Sonya L. Heath, Hugo Perazzo, Kathleen E. Corey, Todd T. Brown, Alan Landay, Fred R. Sattler, Kristine M. Erlandson
Abstract
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636 and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. MRI acquisition and reading were supported by the McGovern Medical School at UTHealth Houston.
Topics & Concepts
MedicineSemaglutideHuman immunodeficiency virus (HIV)DiseaseDiabetes mellitusInternal medicineLiver dysfunctionFatty liverSteatosisType 2 diabetesImmunologyEndocrinologyLiraglutideLiver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementMetabolism, Diabetes, and Cancer